Release dates
Date
Latest Press Release
August 20th, 2019
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
June 17th, 2019
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
May 17th, 2019
Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer
May 9th, 2019
Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
April 17th, 2019
Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock – 4/17/2019
April 17th, 2019
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 4/17/2019
April 15th, 2019
Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors
March 20th, 2019
Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019
March 14th, 2019
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 13th, 2019
Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019
March 11th, 2019
Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit
February 27th, 2019
Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer
February 5th, 2019
Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
January 7th, 2019
Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
December 19th, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
December 18th, 2018
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
December 17th, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
December 3rd, 2018
Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
December 3rd, 2018
Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
October 23rd, 2018
Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
October 17th, 2018
Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
October 16th, 2018
Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
October 16th, 2018
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
September 24th, 2018
Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
March 26th, 2018
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
March 21st, 2018
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
March 12th, 2018
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
March 6th, 2018
Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March
March 5th, 2018
Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
February 6th, 2018
Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
January 16th, 2018
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
January 8th, 2018
Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
January 3rd, 2018
Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
October 31st, 2017
Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional Shares
October 2nd, 2017
Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting
September 18th, 2017
Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors – Company Advancing Multiple Programs in Orphan Disease Pipeline
September 5th, 2017
Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
August 8th, 2017
Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th
July 27th, 2017
Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
July 24th, 2017
Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
June 29th, 2017
Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
June 14th, 2017
Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
June 6th, 2017
Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
May 30th, 2017
Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th
May 17th, 2017
Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
May 15th, 2017
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
April 24th, 2017
Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
April 21st, 2017
Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017
April 6th, 2017
Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
March 23rd, 2017
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
January 30th, 2017
Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
December 12th, 2016
Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)
November 29th, 2016
Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH)
November 14th, 2016
Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting
October 24th, 2016
Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection
October 17th, 2016
Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)
October 13th, 2016
Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting
September 7th, 2016
Eiger Announces Completion of Dosing in Phase 2 LOWR HDV – 4 Study at Hannover Medical School
September 6th, 2016
Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
September 1st, 2016
Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016
August 10th, 2016
Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results – Four Product Candidates in Four Orphan Indications Advancing Toward Near-Term Milestones
July 28th, 2016
Eiger BioPharmaceuticals Announces Partnership with the Hepatitis B Foundation – Raising Awareness of Hepatitis Delta Virus Co-Infection
July 20th, 2016
Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV – 3 Study at National Institutes of Health (NIH)
July 18th, 2016
Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
July 6th, 2016
Eiger BioPharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12th
April 20th, 2016
Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated Interferon Lambda-1a from Bristol-Myers Squibb
April 4th, 2016
Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. “Chuck” Bramlage
March 28th, 2016
Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency
March 9th, 2016
ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote “FOR” Proposed Merger
November 30th, 2015
Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension
November 11th, 2015
Eiger Bio Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University
November 10th, 2015
Eiger Bio Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University
November 9th, 2015
Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex) for Inflammatory Diseases Involving LTB4
October 20th, 2015
Eiger Bio Appoints Eduardo Martins, MD, DPhil, as Senior VP, Liver and Infectious Diseases Drug Development
July 20th, 2015
The Lancet Publishes Results of Phase 2 Study of Lonafarnib in HDV Infected Patients
April 20th, 2015
FDA Grants Fast Track Designation to Eiger Bio’s Lonafarnib for Hepatitis Delta Virus (HDV) Infection
December 23rd, 2014
Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for Hepatitis Delta Virus (HDV) Infection